Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 153

Results For "CAS"

1859 News Found

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey
News | January 31, 2022

Foreign Direct Investment in pharma grows at rapid pace: Eco Survey

In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21


Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance
Hospitals | January 30, 2022

Union Budget 2022-23 : Industry expects increased allocation to healthcare, skill development, R&D and universal health insurance

Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022


Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation
Medical Device | January 30, 2022

Union Budget 2022-23 : Medtech expects incentives, GST exemptions and custom duty rationalisation

Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player


Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
Biotech | January 29, 2022

Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate

Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China


Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion
News | January 28, 2022

Biogen sells equity stake in its biosimilar JV with Samsung Biologics for US $ 2.3 billion

The companies will continue with their exclusive agreements, including commercialization of their current portfolio


Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021


Minimizing API losses critical to responsible pharma manufacturing
News | January 27, 2022

Minimizing API losses critical to responsible pharma manufacturing

Antibiotics mixed in wastewater often get disposed of into the water bodies resulting in wider antimicrobial resistance cases


Mark Cuban’s online pharmacy set to disrupt drug prices in the US
News | January 27, 2022

Mark Cuban’s online pharmacy set to disrupt drug prices in the US

Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals


Cipla’s Q3FY22 PAT at Rs 729 cr.
News | January 26, 2022

Cipla’s Q3FY22 PAT at Rs 729 cr.

Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.


Mandaviya reviews public health preparedness to Covid-19
Policy | January 26, 2022

Mandaviya reviews public health preparedness to Covid-19

Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation